Dludla Phiwayinkosi V, Nkambule Bongani B, Nyambuya Tawanda M, Ziqubu Khanyisani, Mabhida Sihle E, Mxinwa Vuyolwethu, Mokgalaboni Kabelo, Ndevahoma Fransina, Hanser Sidney, Mazibuko-Mbeje Sithandiwe E, Basson Albertus K, Sabbatinelli Jacopo, Tiano Luca
Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South Africa.
Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, South Africa.
Front Nutr. 2022 Oct 31;9:1011002. doi: 10.3389/fnut.2022.1011002. eCollection 2022.
Vitamin C is one of the most consumed dietary compounds and contains abundant antioxidant properties that could be essential in improving metabolic function. Thus, the current systematic review analyzed evidence on the beneficial effects of vitamin C intake on cardiovascular disease (CVD)-related outcomes in patients with diabetes or metabolic syndrome.
To identify relevant randomized control trials (RCTs), a systematic search was run using prominent search engines like PubMed and Google Scholar, from beginning up to March 2022. The modified Black and Downs checklist was used to assess the quality of evidence.
Findings summarized in the current review favor the beneficial effects of vitamin C intake on improving basic metabolic parameters and lowering total cholesterol levels to reduce CVD-risk in subjects with type 2 diabetes or related metabolic diseases. Moreover, vitamin C intake could also reduce the predominant markers of inflammation and oxidative stress like C-reactive protein, interleukin-6, and malondialdehyde. Importantly, these positive outcomes were consistent with improved endothelial function or increased blood flow in these subjects. Predominantly effective doses were 1,000 mg/daily for 4 weeks up to 12 months. The included RCTs presented with the high quality of evidence.
Clinical evidence on the beneficial effects of vitamin C intake or its impact on improving prominent markers of inflammation and oxidative stress in patients with diabetes is still limited. Thus, more RCTs are required to solidify these findings, which is essential to better manage diabetic patients at increased risk of developing CVD.
维生素C是摄入量最高的膳食化合物之一,具有丰富的抗氧化特性,这可能对改善代谢功能至关重要。因此,本系统评价分析了维生素C摄入对糖尿病或代谢综合征患者心血管疾病(CVD)相关结局有益影响的证据。
为了识别相关的随机对照试验(RCT),使用PubMed和谷歌学术等著名搜索引擎进行了系统检索,检索时间从开始到2022年3月。采用改良的Black和Downs清单评估证据质量。
本综述总结的研究结果支持维生素C摄入对改善基本代谢参数和降低总胆固醇水平的有益作用,从而降低2型糖尿病或相关代谢疾病患者的CVD风险。此外,摄入维生素C还可以降低炎症和氧化应激的主要标志物,如C反应蛋白、白细胞介素-6和丙二醛。重要的是,这些积极结果与这些受试者内皮功能改善或血流增加一致。主要有效剂量为每天1000毫克,持续4周直至12个月。纳入的随机对照试验具有高质量的证据。
关于维生素C摄入的有益作用或其对改善糖尿病患者炎症和氧化应激主要标志物的影响的临床证据仍然有限。因此,需要更多的随机对照试验来巩固这些发现,这对于更好地管理有患心血管疾病风险的糖尿病患者至关重要。